LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices

Core Points - LB Pharmaceuticals Inc has been included in the Russell 2000 and Russell 3000 indices, effective December 22, 2025, marking a significant milestone for the company following its recent IPO [1][2] - The inclusion is expected to enhance investor awareness as the company approaches key clinical trials for its lead product candidate, LB-102, targeting schizophrenia and bipolar depression [2][6] - The Russell indexes are widely utilized by investment managers and institutional investors, with approximately $10.6 trillion in assets benchmarked against them as of June 2024 [3] Company Overview - LB Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases [6] - The company is advancing its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the U.S. [6] - If approved, LB-102 could become a key treatment option, providing an alternative to existing branded and generic therapeutics [6] Industry Context - FTSE Russell, the provider of the Russell indexes, is a global leader in index benchmarking, with approximately $18.1 trillion benchmarked to its indexes [4] - The Russell indexes capture the largest U.S. stocks, ranking them by market capitalization, and membership is determined by objective criteria [2][3] - The annual reconstitution of the Russell indexes reflects the dynamic nature of the market, impacting investment strategies and fund allocations [2][3]